Jonah Feldman

The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

The FDA granted fast track designation to a GPRC5D bispecific T-cell engager for multiple myeloma following positive safety and response outcomes in a dose escalation trial.

FDA approves D-VRd, a groundbreaking treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, enhancing survival rates.

The FDA awarded fast track designation to a trispecific antibody targeting BCMA, GPRC5D, and CD3 in multiple myeloma.

The FDA gave breakthrough therapy designation to bezuclastinib plus sunitinib in imatinib-refractory gastrointestinal stromal tumors.

The FDA gave clearance to the IND for a randomized trial of the DNA vaccine iSCIB1+ based on positive single-arm data in combination with dual checkpoint inhibitors.

Higher doses of anti-T-lymphocyte globulin significantly reduce chronic graft-vs-host disease in matched sibling stem cell transplants, enhancing patient outcomes.

The FDA released draft guidance on minimal residual disease and complete response as trial end points to accelerate multiple myeloma drug approvals.

Nivolumab after CAR T-cell therapy failure produced responses in only a small percentage of patients with myeloma or non-Hodgkin lymphoma, although responses in myeloma appeared durable.

In an interview with Targeted Oncology, George Mulligan, PhD, discussed the key takeaways from analysis of the Immune Atlas for multiple myeloma and what will come next now that this data set has been made available.

The FDA granted Orphan Drug Designation to LP-284, a small molecule targeting DNA damage repair mechanisms, for soft tissue sarcoma.

An mRNA neoantigen therapy maintained long-term recurrence-free survival as an adjuvant for melanoma, compared with pembrolizumab alone.

Topline results from the MajesTEC-9 study showed superior progression-free survival and overall survival for teclistamab in patients with 1 to 3 prior lines of treatment for multiple myeloma.

A single-cell atlas of patients with multiple myeloma has identified specific immune signatures that predict patient outcomes and treatment responses beyond traditional cytogenetic risk factors.

A retrospective study of patients treated with an alternate dose schedule of ipilimumab plus nivolumab in advanced melanoma found improvements in both tolerability and efficacy.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.

Giredestrant combined with everolimus significantly improves progression-free survival in advanced ER+, HER2-negative breast cancer after CDK4/6 inhibitors.

Azacitidine plus venetoclax significantly enhances event-free survival and quality of life in acute myeloid leukemia patients compared with traditional chemotherapy.

Physicians at VCU's Massey Comprehensive Cancer Center explored their experiences using tumor-infiltrating lymphocytes to treat patients with advanced melanoma.

In an interview with Targeted Oncology, David J. Benjamin, MD, discussed findings on the global oncology workforce and their implications of insufficient access to cancer care.

In an interview with Targeted Oncology, Frederick L. Locke, MD, discussed how the elimination of the REMS program for CAR T-cell therapy came about and what effects he hopes this will have on patient access.

Iza-bren shows significant improvement in response rates for recurrent nasopharyngeal carcinoma compared to chemotherapy, offering new hope for patients.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

In an interview with Targeted Oncology, Justin Watts, MD spoke about the long-term durability findings with olutasidenib and the next steps for IDH inhibitors in AML.

In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable biopsy an area that has attracted new interest among lung cancer specialists.

Experts explore advancements in bronchoscopic biopsies for lung cancer, emphasizing safety, sample adequacy, and the importance of rapid biomarker testing.